ImmunoCellular Therapeutics, Ltd.
IMUC
Price:
$0.17
Market Cap:
$19.26M
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New ...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
PNK
Ticker
IMUC
The PE Ratio as of November 2024 (TTM) for ImmunoCellular Therapeutics, Ltd. (IMUC) is 0.02
According to ImmunoCellular Therapeutics, Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 0.02. This represents a change of -100.16% compared to the average of -12.49 of the last 4 quarters.
ImmunoCellular Therapeutics, Ltd. (IMUC) Historical PE Ratio (quarterly & annually)
How has IMUC PE Ratio performed in the past?
The mean historical PE Ratio of ImmunoCellular Therapeutics, Ltd. over the last ten years is -9.35. The current 0.02 PE Ratio has changed -121.38% with respect to the historical average. Over the past ten years (40 quarters), IMUC's PE Ratio was at its highest in in the September 2011 quarter at 265.81. The PE Ratio was at its lowest in in the June 2013 quarter at -173.55.
Average
-9.35
Median
-6.28
Minimum
-35.08
Maximum
-0.25
ImmunoCellular Therapeutics, Ltd. (IMUC) PE Ratio by Quarter and Year
Discovering the peaks and valleys of ImmunoCellular Therapeutics, Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.94%
Maximum Annual PE Ratio = -0.25
Minimum Annual Increase = -89.77%
Minimum Annual PE Ratio = -35.08
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -16.29 | -53.55% |
| 2022 | -35.08 | 392.52% |
| 2021 | -7.12 | -51.15% |
| 2020 | -14.58 | 1.94% |
| 2017 | -0.72 | 191.68% |
| 2016 | -0.25 | -89.77% |
| 2015 | -2.40 | -47.37% |
| 2014 | -4.56 | -20.62% |
| 2013 | -5.74 | -15.88% |
| 2012 | -6.82 | -56.66% |
ImmunoCellular Therapeutics, Ltd. (IMUC) Average PE Ratio
How has IMUC PE Ratio performed in the past?
The current PE Ratio of ImmunoCellular Therapeutics, Ltd. (IMUC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-19.50
5-year avg
-14.76
10-year avg
-9.35
ImmunoCellular Therapeutics, Ltd. (IMUC) PE Ratio vs. Peers
How is IMUC’s PE Ratio compared to its peers?
ImmunoCellular Therapeutics, Ltd.’s PE Ratio is greater than Northwest Biotherapeutics, Inc. (-4.63), less than Catalyst Pharmaceuticals, Inc. (17.89), greater than Oxford Cannabinoid Technologies Holdings Plc (-1.11), greater than Pharming Group N.V. (-29.32), less than Kane Biotech Inc. (18.90), less than Health Sciences Group, Inc. (0), greater than MedMira Inc. (-17.98), less than Longboard Pharmaceuticals, Inc. (0), greater than Lumos Pharma, Inc. (-30.52), greater than Cellectar Biosciences, Inc. (-1.03), greater than Bolt Biotherapeutics, Inc. (-1.39), greater than null (-0.34),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.63 | $355.50M | |
| 17.89 | $2.56B | |
| -1.11 | $3.05M | |
| -29.32 | $509.44M | |
| 18.90 | $10.16M | |
| 0 | $187.09K | |
| -17.98 | $41.37M | |
| 0 | $2.33B | |
| -30.52 | $37.28M | |
| -1.03 | $65.21M | |
| -1.39 | $22.14M | |
| -0.34 | $0 |
Build a custom stock screener for ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoCellular Therapeutics, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ImmunoCellular Therapeutics, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is ImmunoCellular Therapeutics, Ltd.'s PE Ratio?
How is the PE Ratio calculated for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the highest PE Ratio for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the 3-year average PE Ratio for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the 5-year average PE Ratio for ImmunoCellular Therapeutics, Ltd. (IMUC)?
How does the current PE Ratio for ImmunoCellular Therapeutics, Ltd. (IMUC) compare to its historical average?